tailieunhanh - Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: Study protocol for a randomized controlled trial

Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine therapy is an effective strategy to improve progression-free survival in hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. | Selecting the optimal position of CDK4 6 inhibitors in hormone receptor-positive advanced breast cancer the SONIA study Study protocol for a randomized controlled trial

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN